Antibody drug conjugatetro Trodelvy significantly improves PFS: Phase III study reaches end in patients with triple-negative breast cancer
-
Last Update: 2020-07-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Immunomedics announced that its antibody drug, the conjugate Trotecan-hziy, was used in patients with three negativebreast cancer(TNBC), who had previously received at least two anti-metastasis therapies, and that the Phase III ASCENT study reached the primary end point of progression-free survival (PFS)Photo Source:Trodelvy is made up of the highly expressed TROP-2 monoantidotophobic drug (Iliticon) SN-38, an antibody drug conjugate that was approved by theFDAearlier this year for metastatic TNBC patients who have received at least two treatmentsTrodelvy's accelerated approval was based on Phase II studies, which showed an objective mitigation rate of 33.3% and a mitigation time of 7.7 monthsIn the ASCENT trial, median PFS was 5.6 months for patients treated with Trodelvy, compared with 1.7 months for chemotherapy, ByEMedics saidThe drug also reached the primary secondary endpoint of the study, including overall survival and objective mitigation ratesThe ASCENT study recruited more than 500 metastatic TNBC patients who had previously received at least two treatments for breast cancer metastasisThe safety of Trodelvy in the trial was consistent with FDA-approved labels, and neutrophil reduction and diarrhea were the most common level 3 or 4 adverse events
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
